University of California San Francisco

Publications

  1. Adipocyte inflammation is the primary driver of hepatic insulin resistance in a human iPSC-based microphysiological system.
    2024 | PubMed
  2. Human Hepatocytes Can Give Rise to Intrahepatic Cholangiocarcinomas.
    2024 | PubMed
  3. Modeling and therapeutic targeting of inflammation-induced hepatic insulin resistance using human iPSC-derived hepatocytes and macrophages.
    2023 | PubMed
  4. Human iPSC-Derived Proinflammatory Macrophages cause Insulin Resistance in an Isogenic White Adipose Tissue Microphysiological System.
    2023 | PubMed
  5. Reply.
    2022 | PubMed
  6. Aquaporin 9 induction in human iPSC-derived hepatocytes facilitates modeling of ornithine transcarbamylase deficiency.
    2021 | PubMed
  7. Integrated Isogenic Human Induced Pluripotent Stem Cell-Based Liver and Heart Microphysiological Systems Predict Unsafe Drug-Drug Interaction.
    2021 | PubMed
  8. Induced Pluripotent Stem Cell-derived Hepatocytes From Patients With Nonalcoholic Fatty Liver Disease Display a Disease-specific Gene Expression Profile.
    2021 | PubMed
  9. Emerging cell therapy for biliary diseases.
    2021 | PubMed
  10. Transcriptomic Traces of Adult Human Liver Progenitor Cells.
    2020 | PubMed
  11. Broad Distribution of Hepatocyte Proliferation in Liver Homeostasis and Regeneration.
    2019 | PubMed
  12. Hepatocyte Nuclear Factor 4 Alpha Activation Is Essential for Termination of Liver Regeneration in Mice.
    2019 | PubMed
  13. De novo formation of the biliary system by TGFβ-mediated hepatocyte transdifferentiation.
    2018 | PubMed
  14. Postnatal Organogenesis by Transdifferentiation.
    2018 | UCSF Research Profile
  15. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.
    2016 | PubMed
  16. In Vivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis.
    2016 | PubMed
  17. Assessing the therapeutic potential of lab-made hepatocytes.
    2016 | PubMed
  18. Physiological ranges of matrix rigidity modulate primary mouse hepatocyte function in part through hepatocyte nuclear factor 4 alpha.
    2016 | PubMed
  19. A screen in mice uncovers repression of lipoprotein lipase by microRNA-29a as a mechanism for lipid distribution away from the liver.
    2014 | PubMed
  20. AAV8-mediated in vivo overexpression of miR-155 enhances the protective capacity of genetically attenuated malarial parasites.
    2014 | PubMed
  21. Evidence against a Stem Cell Origin of New Hepatocytes in a Common Mouse Model of Chronic Liver Injury.
    2014 | UCSF Research Profile
  22. Evidence against a stem cell origin of new hepatocytes in a common mouse model of chronic liver injury.
    2014 | PubMed
  23. Brief report: Parthenogenetic embryonic stem cells are an effective cell source for therapeutic liver repopulation.
    2014 | PubMed
  24. Failure to achieve normal metabolic response in non-obese diabetic mice and streptozotocin-induced diabetic mice after transplantation of primary murine hepatocytes electroporated with the human proinsulin gene (p3MTChins).
    2014 | PubMed
  25. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.
    2014 | PubMed
  26. Mouse liver repopulation with hepatocytes generated from human fibroblasts.
    2014 | PubMed
  27. Addendum: A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice.
    2014 | PubMed
  28. Human induced pluripotent stem cell-based microphysiological tissue models of myocardium and liver for drug development.
    2013 | PubMed
  29. MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer.
    2013 | PubMed
  30. Transplantable liver organoids made from only three ingredients.
    2013 | PubMed
  31. Highly efficient differentiation of functional hepatocytes from human induced pluripotent stem cells.
    2013 | PubMed
  32. A therapy for liver failure found in the JNK yard.
    2013 | PubMed
  33. Akt/Notch activation drives rapid cholangiocarcinoma development originating from mature hepatocytes in the mouse.
    2013 | UCSF Research Profile
  34. Cholangiocarcinomas can originate from hepatocytes in mice.
    2012 | PubMed
  35. A ZFN/piggyBac step closer to autologous liver cell therapy.
    2012 | PubMed
  36. A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration.
    2012 | PubMed
  37. Stem cells in liver diseases and cancer: recent advances on the path to new therapies.
    2012 | PubMed
  38. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration.
    2011 | PubMed
  39. A simple code for installing hepatocyte function.
    2011 | PubMed
  40. Mouse chimeras as a system to investigate development, cell and tissue function, disease mechanisms and organ regeneration.
    2011 | PubMed
  41. Core promoter recognition complex changes accompany liver development.
    2011 | PubMed
  42. The MAP3K TAK1: a chock block to liver cancer formation.
    2010 | PubMed
  43. Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice.
    2010 | PubMed
  44. Transplanted nonviable human hepatocytes produce appreciable serum albumin levels in mice.
    2010 | PubMed
  45. miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues.
    2010 | PubMed
  46. Therapeutic liver reconstitution with murine cells isolated long after death.
    2010 | PubMed
  47. MicroRNAs control hepatocyte proliferation during liver regeneration.
    2010 | PubMed
  48. Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis.
    2008 | PubMed
  49. ????????in vitro???.
    2008 | UCSF Research Profile
  50. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice.
    2008 | PubMed
  51. On the origin of the term "stem cell".
    2007 | PubMed
  52. Myeloid lineage progenitors give rise to vascular endothelium.
    2006 | PubMed
  53. Bone marrow-derived cells fuse with normal and transformed intestinal stem cells.
    2006 | PubMed
  54. Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases.
    2006 | PubMed
  55. Myeloid Lineage-Restricted Progenitors Contribute to Vascular Endothelium.
    2005 | UCSF Research Profile
  56. In vivo genetic selection of renal proximal tubules.
    2005 | PubMed
  57. Therapeutic cell fusion.
    2005 | PubMed
  58. Delineating the hepatocyte's hematopoietic fusion partner.
    2004 | PubMed
  59. Myelomonocytic cells are sufficient for therapeutic cell fusion in liver.
    2004 | PubMed
  60. Embryonic versus adult stem cell pluripotency: in liver only fusion matters.
    2003 | PubMed
  61. Cell fusion is the principal source of bone-marrow-derived hepatocytes.
    2003 | PubMed
  62. Argininosuccinate lyase (ASL) deficiency: mutation analysis in 27 patients and a completed structure of the human ASL gene.
    2002 | PubMed
  63. Genomic structure and transcript variants of the human methylenetetrahydrofolate reductase gene.
    2000 | PubMed
  64. Telomerase activity distinguishes between neuroblastomas with good and poor prognosis.
    1999 | PubMed
  65. Telomerase activity in human proliferative breast lesions.
    1998 | PubMed
  66. Nonisotopic single strand conformation analysis of the 5 alpha-reductase type 2 gene for the diagnosis of 5 alpha-reductase deficiency.
    1996 | PubMed
  67. Molecular genetic analysis and human chorionic gonadotropin stimulation tests in the diagnosis of prepubertal patients with partial 5 alpha-reductase deficiency.
    1996 | PubMed